These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 20727796)

  • 1. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D; Cohn GM; Wang N; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jan; 46(1):119-23. PubMed ID: 20727796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction.
    Elstein D; Foldes AJ; Zahrieh D; Cohn GM; Djordjevic M; Brutaru C; Zimran A
    Blood Cells Mol Dis; 2011 Jun; 47(1):56-61. PubMed ID: 21536468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
    Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE; Turkia HB; Lukina EA; Kisinovsky I; Dridi MF; Elstein D; Zahrieh D; Crombez E; Bhirangi K; Barton NW; Zimran A
    Am J Hematol; 2013 Mar; 88(3):166-71. PubMed ID: 23386328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
    Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
    Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
    Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
    Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A; Elstein D; Gonzalez DE; Lukina EA; Qin Y; Dinh Q; Turkia HB
    Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
    Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract]   [Full Text] [Related]  

  • 15. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.
    Hollak CE; de Fost M; van Dussen L; Vom Dahl S; Aerts JM
    Expert Opin Pharmacother; 2009 Nov; 10(16):2641-52. PubMed ID: 19743939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of velaglucerase alfa enzyme replacement therapy on red blood cell properties in Gaucher disease.
    Franco M; Reihani N; Marin M; De Person M; Billette de Villemeur T; Rose C; Colin Y; Moussa F; Belmatoug N; Le Van Kim C
    Am J Hematol; 2017 Sep; 92(9):E561-E563. PubMed ID: 28621801
    [No Abstract]   [Full Text] [Related]  

  • 20. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
    Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.